This certificate will strengthen the Company to enter the European Regulated Market for Metformin Hydrochloride. This certificate will have a substantial ...
... has granted final approval for its Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
... for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl). Glipizide/Metformin HCl is indicated as ...
GLUMETZA(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in Canada by ...
GLUMETZATM (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in Canada by Biovail ...
GLUMETZA(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in Canada by ...
Glumetza™ (metformin hydrochloride) extended-release tablets in 500mg and 1000mg dosage strengths are indicated for the control of hyperglycemia in adult ...
This one is for the manufacture of lipizide/metformin hydrochloride tablets, a generic version of Bristol-Myers Squibb’s Metaglip. ...
... Abbreviated New Drug Application (ANDA) for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl). ...
... Abbreviated New Drug Application (ANDA) for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl). ...